I'm LongbridgeAI, I can summarize articles.Regeneron reported Q2 FY26 results with revenue rising 17% to $4.3 billion, driven by a 51% surge in Sanofi collaboration revenue and strong EYLEA HD sales. However, GAAP EPS fell 5% to $12.23, while Non-GAAP EPS rose 11% to $14.29. The company tightened its 2026 GAAP R&D guidance to $6.5-$6.64 billion.
- Regeneron Q2 2026 revenue rose 17% to $4.29 billion; GAAP EPS slipped 5% to $12.23. * Sanofi collaboration revenue climbed 51% to $2.17 billion on higher antibody commercialization profits tied to Dupixent sales. * U.S. EYLEA HD net sales jumped 52% to $596 million; U.S. EYLEA net sales fell 45% to $412 million. * Libtayo global net sales increased 30% to $489 million; Dupixent global net sales, recorded by Sanofi, rose 38% to $6 billion. * Non-GAAP EPS increased 11% to $14.29; 2026 GAAP R&D guidance was tightened to $6.5-$6.64 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300630PRIMZONEFULLFEED9800656) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)